Valiance Partners Europe, Ltd., created in response to its clients’ worldwide growth and global scale projects
Basking Ridge, NJ December 1, 2015—Valiance Partners, known in the FDA regulated market for its TRUseries suite of products for migrating GxP data and content, announces the formation of Valiance Partners Europe, Ltd., headquartered in Dublin, Ireland. With the expansion into Europe, Valiance can support its clients both locally and internationally. Valiance itself has experienced rapid growth generated by its software partners and direct clients, each of which recognize the value, cost savings and migration accuracies derived from Valiance’s technology.
“The increase in larger scale M&A activity is driving the need for worldwide solutions for GxP information systems consolidations. Valiance is also seeing an increased demand from EU clients looking for a local presence and the ability to compensate in Euros,” said Valiance Partners President and CEO, Rick Higger. “After looking at a number of locations throughout Europe, it became clear that the technical talent made the decision to move to Dublin very simple. In addition, many of our almost 100 life science clients have a major presence in Ireland, and specifically in Dublin, which assisted in the decision to locate there.”
Valiance Partners is the leading vendor for high-risk data and content migrations where compliance and business risk demand “getting it right.” For more than eight years, Valiance has managed hundreds of successful migrations for the world’s leading pharmaceutical, medical device and biotechnology brands. They bring an unparalleled knowledge of regulations, business processes and precision results to every client engagement.
Valiance’s software products, TRUmigrate, TRUcompare and TRUconsole, provide end-to-end data and content migration software solutions for IT, quality, validation and test management. In addition, our professional services help clients embark on migrations with the technology, business and compliance knowledge needed to succeed in regulated industries.
Migrations are a complex undertaking and traditional testing approaches often fall short of today’s business and compliance requirements. The ensuing risk can easily result in costly errors. The question is: How sound are your current testing and sampling approaches?